Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Last month, the Food and Drug Administration approved that molecule, now called Journavx, as a treatment for the sharp, short-lived “acute” pain usually felt after an accident or a surgery.

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

This is the first new type of pain medication to be approved in more than 20 years It is anticipated that payers will see an up-tick in the number of requests for this new drug. Journavx will ...

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...

Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...

Opioid pain relievers come with many side ... Dr. Thomas: “Yeah, I think that will be occurring. I mean, many drugs are prescribed off-label.” Journavx can be taken with ibuprofen for its ...

Journavx is the first in a new class of pain medications that do not rely on opioids and are typically prescribed following surgeries or traumatic injuries. Dr. Andrew Revelis with Hillcrest ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...